FDA clears Lab21's syphilis test
This article was originally published in Clinica
UK firm Lab21 has received its first 510(k) clearance from the US FDA, for its syphilis test. The assay detects Treponema pallidum haemagglutination (TPHA) – this bacterium causes the sexually transmitted infection. The Syphilis THPA test runs on Beckman Coulter’s PK7200 platform, and was approved in China in June (www.clinica.co.uk, 4 June 2010). Meanwhile, Cambridge-based Lab21 has launched its cytomegalovirus haemagglutination (CMV HA) assay in Europe, after CE marking the product last month. The test can be carried out on Beckman Coulter’s PK7200 and 7300 systems. CMV generally causes few symptoms, but can lead to significant health problems in immunocompromised people.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.